In a phase II clinical trial sponsored by Roche (NCT03563716), anti-TIGIT mAb (Tiragolumab) was granted breakthrough therapy designation and was tested in combination with anti-PD-L1 (atezolizumab) in metastatic NSCLC (128). Here, CD274 is linked to non-small cell lung carcinoma.